1. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
- Author
-
Guglielmetti L, Barkane L, Le Dû D, Marigot-Outtandy D, Robert J, Veziris N, Yazdanpanah Y, Kuksa L, Caumes E, and Fréchet-Jachym M
- Subjects
- Adult, Antitubercular Agents adverse effects, Clinical Trials as Topic, Diarylquinolines adverse effects, Drug Administration Schedule, France, Humans, Latvia, Male, Nitroimidazoles adverse effects, Oxazoles adverse effects, Patient Safety, Treatment Outcome, Antitubercular Agents administration & dosage, Diarylquinolines administration & dosage, Nitroimidazoles administration & dosage, Oxazoles administration & dosage, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
Competing Interests: Conflict of interest: L. Guglielmetti belonged to a research team that received research grants from Janssen Pharmaceuticals, outside the submitted work. Conflict of interest: L. Barkane was sub-investigator in the delamanid trial 213 and presented the Latvian experience with delamanid in the ERS congress 2016. Conflict of interest: J. Robert belonged to a research team that received research grants from Janssen Pharmaceuticals, outside the submitted work. Conflict of interest: N. Veziris received financial support for attending the 48th Union World Conference on Lung Health from Otsuka, outside the submitted work. Conflict of interest: Y. Yazdanpanah has been a board member receiving consultancy fees from ABBVIE, BMS, Gilead, MSD, J&J, Pfizer and ViiV Healthcare until November 2016. Conflict of interest: L. Kuksa was an investigator in the delamanid trials 204, 208 and 213 and presented Latvia experience with the compound at the launching conference in Korea.
- Published
- 2018
- Full Text
- View/download PDF